Industry Research Reports

Home > Reports > Medical Care > Global Duchenne Muscular Dystrophy Drugs Market Insights, Forecast to 2030

Global Duchenne Muscular Dystrophy Drugs Market Insights, Forecast to 2030

Industry: Medical Care

Published: 2024-04-28

Pages: 114 Pages

Report ld: 3113486

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Market Analysis and Insights: Global Duchenne Muscular Dystrophy Drugs Market
The global Duchenne Muscular Dystrophy Drugs market is projected to grow from US$ 1399.3 million in 2024 to US$ 8086.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 34.0% during the forecast period.

Duchenne Muscular Dystrophy Drugs Market Size

M= millions and B=billions

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:
This report presents an overview of global market for Duchenne Muscular Dystrophy Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Duchenne Muscular Dystrophy Drugs, also provides the revenue of main regions and countries. of the upcoming market potential for Duchenne Muscular Dystrophy Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Duchenne Muscular Dystrophy Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Duchenne Muscular Dystrophy Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Duchenne Muscular Dystrophy Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Biogen, Roche, Daiichi Sankyo, Pfizer, Cumberland Pharmaceuticals, Santhera Pharmaceuticals, Taiho Pharmaceutical, Teijin Pharma and Akashi Therapeutics, etc.

Market Segmentation

Report Metric
Details
Report Title
Global Duchenne Muscular Dystrophy Drugs Market Insights, Forecast to 2030
Forecasted Market Size in 2030
US$ 8086.7 million
CAGR(2024-2030)
34%
Market Size Available for Years
2019-2030
Global Duchenne Muscular Dystrophy Drugs Companies Covered
Biogen, Roche, Daiichi Sankyo, Pfizer, Cumberland Pharmaceuticals, Santhera Pharmaceuticals, Taiho Pharmaceutical, Teijin Pharma, Akashi Therapeutics, Sarepta Therapeutics, BioMarin, Fibrogen Inc, Nobelpharma Co. Ltd, Eloxx Pharmaceuticals
Global Duchenne Muscular Dystrophy Drugs Market, Segment by Type
Molecular-based Therapies

Steroid Therapy

Other
Global Duchenne Muscular Dystrophy Drugs Market, Segment by Application
Hospitals

Clinics

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Duchenne Muscular Dystrophy Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

 1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
        1.2.2 Molecular-based Therapies
        1.2.3 Steroid Therapy
        1.2.4 Other
    1.3 Market by Application
        1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2019-2030)
    2.2 Global Duchenne Muscular Dystrophy Drugs Growth Trends by Region
        2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Region: 2019 VS 2023 VS 2030
        2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2019-2024)
        2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2025-2030)
    2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
        2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
        2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
        2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
        2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Revenue Duchenne Muscular Dystrophy Drugs by Players
        3.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2019-2024)
        3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2019-2024)
    3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Global Key Players of Duchenne Muscular Dystrophy Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024
    3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
        3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2023
    3.5 Global Key Players of Duchenne Muscular Dystrophy Drugs Head office and Area Served
    3.6 Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
    3.7 Global Key Players of Duchenne Muscular Dystrophy Drugs, Date of Enter into This Industry
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
    4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2019-2024)
    4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2025-2030)

 5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
    5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2019-2024)
    5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2025-2030)

 6 North America
    6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2019-2030)
    6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type
        6.2.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
        6.2.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030)
        6.2.3 North America Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Application
        6.3.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
        6.3.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030)
        6.3.3 North America Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    6.4 North America Duchenne Muscular Dystrophy Drugs Market Size by Country
        6.4.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
        6.4.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024)
        6.4.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2025-2030)
        6.4.4 U.S.
        6.4.5 Canada

 7 Europe
    7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2019-2030)
    7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type
        7.2.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
        7.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030)
        7.2.3 Europe Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application
        7.3.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
        7.3.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030)
        7.3.3 Europe Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    7.4 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country
        7.4.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
        7.4.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024)
        7.4.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2025-2030)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries

 8 China
    8.1 China Duchenne Muscular Dystrophy Drugs Market Size (2019-2030)
    8.2 China Duchenne Muscular Dystrophy Drugs Market Size by Type
        8.2.1 China Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
        8.2.2 China Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030)
        8.2.3 China Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    8.3 China Duchenne Muscular Dystrophy Drugs Market Size by Application
        8.3.1 China Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
        8.3.2 China Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030)
        8.3.3 China Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)

 9 Asia (excluding China)
    9.1 Asia Duchenne Muscular Dystrophy Drugs Market Size (2019-2030)
    9.2 Asia Duchenne Muscular Dystrophy Drugs Market Size by Type
        9.2.1 Asia Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
        9.2.2 Asia Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030)
        9.2.3 Asia Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    9.3 Asia Duchenne Muscular Dystrophy Drugs Market Size by Application
        9.3.1 Asia Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
        9.3.2 Asia Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030)
        9.3.3 Asia Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    9.4 Asia Duchenne Muscular Dystrophy Drugs Market Size by Region
        9.4.1 Asia Duchenne Muscular Dystrophy Drugs Market Size by Region: 2019 VS 2023 VS 2030
        9.4.2 Asia Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024)
        9.4.3 Asia Duchenne Muscular Dystrophy Drugs Market Size by Region (2025-2030)
        9.4.4 Japan
        9.4.5 South Korea
        9.4.6 China Taiwan
        9.4.7 Southeast Asia
        9.4.8 India
        9.4.9 Australia

 10 Middle East, Africa, and Latin America
    10.1 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size (2019-2030)
    10.2 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type
        10.2.1 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
        10.2.2 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030)
        10.2.3 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    10.3 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application
        10.3.1 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
        10.3.2 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030)
        10.3.3 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    10.4 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country
        10.4.1 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
        10.4.2 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024)
        10.4.3 Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2025-2030)
        10.4.4 Brazil
        10.4.5 Mexico
        10.4.6 Turkey
        10.4.7 Saudi Arabia
        10.4.8 Israel
        10.4.9 GCC Countries

 11 Key Players Profiles
    11.1 Biogen
        11.1.1 Biogen Company Details
        11.1.2 Biogen Business Overview
        11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
        11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.1.5 Biogen Recent Developments
    11.2 Roche
        11.2.1 Roche Company Details
        11.2.2 Roche Business Overview
        11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
        11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.2.5 Roche Recent Developments
    11.3 Daiichi Sankyo
        11.3.1 Daiichi Sankyo Company Details
        11.3.2 Daiichi Sankyo Business Overview
        11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
        11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.3.5 Daiichi Sankyo Recent Developments
    11.4 Pfizer
        11.4.1 Pfizer Company Details
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
        11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.4.5 Pfizer Recent Developments
    11.5 Cumberland Pharmaceuticals
        11.5.1 Cumberland Pharmaceuticals Company Details
        11.5.2 Cumberland Pharmaceuticals Business Overview
        11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.5.5 Cumberland Pharmaceuticals Recent Developments
    11.6 Santhera Pharmaceuticals
        11.6.1 Santhera Pharmaceuticals Company Details
        11.6.2 Santhera Pharmaceuticals Business Overview
        11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.6.5 Santhera Pharmaceuticals Recent Developments
    11.7 Taiho Pharmaceutical
        11.7.1 Taiho Pharmaceutical Company Details
        11.7.2 Taiho Pharmaceutical Business Overview
        11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
        11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.7.5 Taiho Pharmaceutical Recent Developments
    11.8 Teijin Pharma
        11.8.1 Teijin Pharma Company Details
        11.8.2 Teijin Pharma Business Overview
        11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
        11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.8.5 Teijin Pharma Recent Developments
    11.9 Akashi Therapeutics
        11.9.1 Akashi Therapeutics Company Details
        11.9.2 Akashi Therapeutics Business Overview
        11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
        11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.9.5 Akashi Therapeutics Recent Developments
    11.10 Sarepta Therapeutics
        11.10.1 Sarepta Therapeutics Company Details
        11.10.2 Sarepta Therapeutics Business Overview
        11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
        11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.10.5 Sarepta Therapeutics Recent Developments
    11.11 BioMarin
        11.11.1 BioMarin Company Details
        11.11.2 BioMarin Business Overview
        11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
        11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.11.5 BioMarin Recent Developments
    11.12 Fibrogen Inc
        11.12.1 Fibrogen Inc Company Details
        11.12.2 Fibrogen Inc Business Overview
        11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
        11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.12.5 Fibrogen Inc Recent Developments
    11.13 Nobelpharma Co. Ltd
        11.13.1 Nobelpharma Co. Ltd Company Details
        11.13.2 Nobelpharma Co. Ltd Business Overview
        11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
        11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.13.5 Nobelpharma Co. Ltd Recent Developments
    11.14 Eloxx Pharmaceuticals
        11.14.1 Eloxx Pharmaceuticals Company Details
        11.14.2 Eloxx Pharmaceuticals Business Overview
        11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
        11.14.5 Eloxx Pharmaceuticals Recent Developments

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Molecular-based Therapies
    Table 3. Key Players of Steroid Therapy
    Table 4. Key Players of Other
    Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2019-2024)
    Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2025-2030)
    Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
    Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
    Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
    Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
    Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Players (2019-2024)
    Table 17. Global Top Duchenne Muscular Dystrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2023)
    Table 18. Global Duchenne Muscular Dystrophy Drugs Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Duchenne Muscular Dystrophy Drugs, Headquarters and Area Served
    Table 21. Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
    Table 22. Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2019-2024)
    Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2025-2030)
    Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Application (2019-2024)
    Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Application (2025-2030)
    Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Duchenne Muscular Dystrophy Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Duchenne Muscular Dystrophy Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Duchenne Muscular Dystrophy Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Duchenne Muscular Dystrophy Drugs Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Biogen Company Details
    Table 65. Biogen Business Overview
    Table 66. Biogen Duchenne Muscular Dystrophy Drugs Product
    Table 67. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 68. Biogen Recent Developments
    Table 69. Roche Company Details
    Table 70. Roche Business Overview
    Table 71. Roche Duchenne Muscular Dystrophy Drugs Product
    Table 72. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 73. Roche Recent Developments
    Table 74. Daiichi Sankyo Company Details
    Table 75. Daiichi Sankyo Business Overview
    Table 76. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
    Table 77. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 78. Daiichi Sankyo Recent Developments
    Table 79. Pfizer Company Details
    Table 80. Pfizer Business Overview
    Table 81. Pfizer Duchenne Muscular Dystrophy Drugs Product
    Table 82. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 83. Pfizer Recent Developments
    Table 84. Cumberland Pharmaceuticals Company Details
    Table 85. Cumberland Pharmaceuticals Business Overview
    Table 86. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 87. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 88. Cumberland Pharmaceuticals Recent Developments
    Table 89. Santhera Pharmaceuticals Company Details
    Table 90. Santhera Pharmaceuticals Business Overview
    Table 91. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 92. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 93. Santhera Pharmaceuticals Recent Developments
    Table 94. Taiho Pharmaceutical Company Details
    Table 95. Taiho Pharmaceutical Business Overview
    Table 96. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
    Table 97. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 98. Taiho Pharmaceutical Recent Developments
    Table 99. Teijin Pharma Company Details
    Table 100. Teijin Pharma Business Overview
    Table 101. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
    Table 102. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 103. Teijin Pharma Recent Developments
    Table 104. Akashi Therapeutics Company Details
    Table 105. Akashi Therapeutics Business Overview
    Table 106. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
    Table 107. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 108. Akashi Therapeutics Recent Developments
    Table 109. Sarepta Therapeutics Company Details
    Table 110. Sarepta Therapeutics Business Overview
    Table 111. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
    Table 112. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 113. Sarepta Therapeutics Recent Developments
    Table 114. BioMarin Company Details
    Table 115. BioMarin Business Overview
    Table 116. BioMarin Duchenne Muscular Dystrophy Drugs Product
    Table 117. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 118. BioMarin Recent Developments
    Table 119. Fibrogen Inc Company Details
    Table 120. Fibrogen Inc Business Overview
    Table 121. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product
    Table 122. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 123. Fibrogen Inc Recent Developments
    Table 124. Nobelpharma Co. Ltd Company Details
    Table 125. Nobelpharma Co. Ltd Business Overview
    Table 126. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product
    Table 127. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 128. Nobelpharma Co. Ltd Recent Developments
    Table 129. Eloxx Pharmaceuticals Company Details
    Table 130. Eloxx Pharmaceuticals Business Overview
    Table 131. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 132. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2019-2024) & (US$ Million)
    Table 133. Eloxx Pharmaceuticals Recent Developments
    Table 134. Research Programs/Design for This Report
    Table 135. Key Data Information from Secondary Sources
    Table 136. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2023 VS 2030
    Figure 3. Molecular-based Therapies Features
    Figure 4. Steroid Therapy Features
    Figure 5. Other Features
    Figure 6. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2023 VS 2030
    Figure 8. Hospitals Case Studies
    Figure 9. Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Duchenne Muscular Dystrophy Drugs Report Years Considered
    Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2023 VS 2030
    Figure 15. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2023
    Figure 16. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2023
    Figure 18. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    Figure 20. North America Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    Figure 21. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2019-2030)
    Figure 22. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 25. Europe Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    Figure 26. Europe Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    Figure 27. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2019-2030)
    Figure 28. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. China Duchenne Muscular Dystrophy Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 35. China Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    Figure 36. China Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    Figure 37. Asia Duchenne Muscular Dystrophy Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. Asia Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    Figure 39. Asia Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    Figure 40. Asia Duchenne Muscular Dystrophy Drugs Market Share by Region (2019-2030)
    Figure 41. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. China Taiwan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Share by Type (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Share by Application (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2019-2030)
    Figure 51. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Israel Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. GCC Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 58. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 59. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 60. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 61. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 62. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 63. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 64. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 65. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 66. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 67. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 68. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 69. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 70. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2019-2024)
    Figure 71. Bottom-up and Top-down Approaches for This Report
    Figure 72. Data Triangulation
    Figure 73. Key Executives Interviewed

Market Analysis and Insights: Global Duchenne Muscular Dystrophy Drugs Market
The global Duchenne Muscular Dystrophy Drugs market is projected to grow from US$ 1399.3 million in 2024 to US$ 8086.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 34.0% during the forecast period.

Market Segmentation

Industry: Medical Care

Published: 2024-04-28

Pages: 114 Pages

Report ld: 3113486

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 4900.00

Multi Users License

USD 7350.00

Corporate Users License

USD 9800.00

/uploads/payment/payIcon/masterCard-01.svg

/uploads/payment/payIcon/american-express-01.svg

/uploads/payment/payIcon/diners-club-01.svg

/uploads/payment/payIcon/discover-4-01.svg

Add to Cart

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

Speak To Our Analyst >>

WHAT QYRESEARCH OFFER?